Introduction
Indication: Breast and gastric cancer
Originator: Genentech (brand name Herceptin®)
BLA filed in 2021
FDA inspection in 2022
CRL received in 2022
Features / strengths
1. Global clinical trials completed and publisehed in ESMO 2021 and ASCO 2022
2. US FDA Drug Approval: in process
3. Manufactured in USA
Specification in detail
